ANSWER: C

Rationale:

The DOSE trial (Felker et al., N Engl J Med, 2011) compared high-dose (2.5× the oral daily dose) versus low-dose (1× the oral dose equivalent) IV furosemide and continuous infusion versus intermittent bolus dosing in acute decompensated heart failure. The high-dose strategy produced greater decongestion — more weight loss, greater urine output, and better patient-reported symptom scores — at 72 hours compared to low-dose, with a modest non-significant creatinine increase that did not translate into worse 60-day outcomes. For M.V., taking oral furosemide 80 mg twice daily (total daily dose 160 mg), the DOSE-informed high-dose IV strategy is 2.5 × 160 mg = 400 mg daily, divided as approximately 200 mg per day in bolus doses (e.g., 100 mg IV twice daily or 80 mg three times daily). The pharmacokinetic rationale for IV administration is that oral furosemide's bioavailability is highly variable (averaging ~50%, range 10–100%) and is further reduced during acute decompensation because gut wall edema — from elevated venous pressures — impairs intestinal mucosal absorption of furosemide; IV administration bypasses this variability entirely, delivering predictable drug concentrations to the tubular secretion site.

• Option A: Option A is incorrect: a 50% dose reduction is not appropriate for oral-to-IV conversion; the correct strategy is to increase the dose (to 2.5× oral) because the IV route does not lower the effective dose requirement — the IV advantage is bioavailability predictability, not that equivalent natriuresis can be achieved at lower doses.
• Option B: Option B is incorrect: the 1:1 conversion is the low-dose arm of the DOSE trial, which produced inferior decongestion compared to 2.5× dosing; while 1:1 conversion avoids creatinine risk, it also provides less effective decongestion, and current practice favors the high-dose strategy.
• Option D: Option D is incorrect: DOSE did not establish a 4× oral dose strategy, and 320 mg IV twice daily (640 mg daily) is not a DOSE-validated protocol; the high-dose arm was specifically 2.5× the oral dose.
• Option E: Option E is incorrect: DOSE found no significant difference between continuous infusion and intermittent bolus dosing for decongestion or renal outcomes; bolus dosing at high dose is the favored practice.

ANSWER: A

Rationale:

The early symptomatic benefit of IV furosemide — which commonly precedes measurable diuresis by 30 minutes or more — is mediated by venodilation driven by prostaglandin synthesis and nitric oxide (NO) release stimulated by furosemide in the renal vasculature and peripheral vessels. This prostaglandin/NO-mediated venodilation reduces systemic venous capacitance, decreases venous return to the right heart, lowers right atrial pressure and pulmonary capillary wedge pressure (preload), and thereby reduces pulmonary venous hypertension — producing rapid dyspnea relief before any meaningful natriuresis occurs. This is also why NSAIDs (non-steroidal anti-inflammatory drugs), which inhibit prostaglandin synthesis, blunt both the early hemodynamic benefit and the renal tubular delivery of furosemide. M.V.'s rapid symptom relief 20 minutes after dosing, while urine output remains unchanged, is entirely consistent with this prostaglandin-mediated venodilatory mechanism.

• Option B: Option B is incorrect: furosemide does not cross the blood-brain barrier in clinically meaningful quantities and has no established mechanism of central neurological dyspnea suppression.
• Option C: Option C is incorrect: NKCC2 is not expressed in pulmonary capillary endothelial cells; furosemide has no direct action on the pulmonary endothelium or alveolar-capillary membrane.
• Option D: Option D is incorrect: IV furosemide solutions are not hyperosmolar in any clinically meaningful way and do not produce oncotic gradients in the lung; this mechanism is fabricated.
• Option E: Option E is incorrect: IV furosemide does not produce reflex tachycardia as an early hemodynamic mechanism of dyspnea relief; the venodilatory mechanism is the established explanation, and tachycardia is not part of the prostaglandin-mediated response.

ANSWER: D

Rationale:

The DOSE trial's key finding on renal outcomes directly addresses this clinical question: high-dose IV furosemide (2.5× the oral dose) produced a modest, non-significant creatinine increase compared to low-dose strategy, and this increase did not translate into worse 60-day outcomes — no significant difference in mortality, rehospitalization, dialysis, or long-term renal function. The critical distinction in applying this evidence to M.V. is volume status assessment: she remains volume overloaded (JVP 10 cm H₂O is still elevated above the normal 6–8 cm H₂O target), is hemodynamically stable (blood pressure 118/72 mmHg, warm extremities), has adequate urine output (100–140 mL/hour), and has no signs of true intravascular volume depletion. This is the definition of acceptable worsening renal function — a modest creatinine rise occurring during effective decongestion in a still-congested, hemodynamically stable patient without hypoperfusion. Furthermore, post-hoc analyses of large HF registries consistently show that persistent congestion at hospital discharge is a significantly stronger predictor of 30-day readmission than an in-hospital creatinine rise during effective diuresis. Reducing furosemide now risks sending M.V. home still congested. Option C is correct in content but is an imprecise distractor — Option D is the more complete and precisely reasoned answer that explicitly integrates the DOSE trial evidence with the clinical volume status assessment and the post-hoc registry data on congestion at discharge.

• Option A: Option A is incorrect: the DOSE trial did not establish 0.3 mg/dL as an upper limit of acceptable WRF requiring mandatory dose reduction; this threshold is fabricated.
• Option B: Option B is incorrect: AHA/ACC/HFSA guidelines do not specify a 25% creatinine rise as a mandatory dose-reduction threshold regardless of volume status; clinical decision-making integrates the full clinical picture, not a single biochemical value.
• Option E: Option E is incorrect: the DOSE trial did not establish a creatinine-based stopping rule of 0.3–0.5 mg/dL as producing better outcomes; this is a fabricated stopping criterion.

ANSWER: B

Rationale:

The pharmacokinetic rationale for torsemide is straightforward and important to communicate accurately to patients. Torsemide is not more potent than furosemide in terms of intrinsic NKCC2-blocking activity — the two drugs are comparable when dosed at equivalent natriuretic doses. The correct potency equivalence ratio is: furosemide 40 mg ≈ torsemide 20 mg ≈ bumetanide 1 mg. For M.V. taking furosemide 160 mg daily (80 mg twice daily), the equivalent torsemide dose is 40 mg daily (once daily). The genuine clinical advantage of torsemide is pharmacokinetic: oral bioavailability of approximately 80–90% (highly consistent across patients and clinical states) compared to furosemide's highly variable 10–100% (average ~50%). This consistency means that torsemide produces reliable and predictable plasma concentrations and diuretic responses from each oral dose, whereas furosemide patients can experience substantial day-to-day variability — which can manifest as unpredictable fluid swings and contributes to unplanned re-admissions. Torsemide is not "stronger" in the sense of greater diuretic potency, and it is important to correct this misconception with M.V. to avoid her misinterpreting the switch as a reduction in her treatment intensity. TRANSFORM-HF confirmed no significant difference in mortality or hospitalization between the two agents, supporting the pharmacokinetically justified preference without claiming mortality superiority.

• Option A: Option A is incorrect: TRANSFORM-HF did not demonstrate that torsemide reduces hospitalizations or mortality compared to furosemide (HR 1.02 for mortality; non-significant composite); the description of torsemide as "guideline-preferred" based on TRANSFORM-HF mortality data is inaccurate.
• Option C: Option C is incorrect: TRANSFORM-HF did not demonstrate inferiority of torsemide in patients with eGFR below 60 mL/min/1.73m²; no such subgroup finding establishes a relative contraindication for torsemide in this eGFR range.
• Option D: Option D is incorrect: the furosemide:torsemide potency ratio is 2:1 (furosemide 40 mg ≈ torsemide 20 mg), not 10:1; a 10:1 ratio would produce a substantially underdosed torsemide regimen.
• Option E: Option E is incorrect: torsemide and furosemide do not have equivalent bioavailability; torsemide's consistent 80–90% versus furosemide's variable 10–100% is the primary pharmacokinetic distinction; and furosemide can be dosed once daily in some patients — it is not exclusively a twice-daily drug. CASE 2 R.T. is a 72-year-old man with HFrEF (LVEF 30%) who has been on furosemide 80 mg twice daily for 19 months. He presents to clinic with 4 kg weight gain over 3 weeks despite medication adherence. Examination shows JVP 14 cm H₂O and 2+ pitting edema. His cardiac output is clinically adequate (warm extremities, normal blood pressure), renal function is stable (eGFR 47 mL/min/1.73m²), albumin is normal (3.9 g/dL), and medication review confirms he is not on any NSAIDs. His echocardiogram is unchanged from 6 months ago.

ANSWER: E

Rationale:

The clinical scenario is specifically constructed to identify the braking phenomenon as the primary resistance mechanism by systematically excluding the other major contributors. Adequate cardiac output eliminates reduced renal perfusion; normal albumin (3.9 g/dL) eliminates hypoalbuminemia as a meaningful mechanism; no NSAID use eliminates prostaglandin inhibition; and eGFR of 47 mL/min/1.73m² — while in the CKD stage 3a range — is not the advanced uremia range where organic acid competition becomes the dominant mechanism (which typically requires eGFR below 30 mL/min/1.73m² for clinical significance). The remaining explanation is the braking phenomenon: 19 months of furosemide-induced chronic NKCC2 blockade has delivered chronically elevated sodium loads to the distal convoluted tubule, stimulating distal tubule cell hypertrophy and transcriptional upregulation of NCC. The enlarged, hypertrophied distal tubule now reabsorbs a substantially greater fraction of the sodium that furosemide delivers past the loop — reducing the sodium that ultimately reaches the collecting duct and appears in the urine. The net natriuresis diminishes progressively until equilibrium is reached between NKCC2 blockade and NCC-mediated reclamation — the pathophysiological basis of the braking phenomenon.

• Option A: Option A is incorrect: albumin of 3.9 g/dL is within the normal range; there is no established 4.0 g/dL threshold below which furosemide-albumin binding kinetics change meaningfully.
• Option B: Option B is incorrect: the clinical examination specifically confirms adequate cardiac output (warm extremities, normal blood pressure), making subclinical low-output physiology an unjustified assumption.
• Option C: Option C is incorrect: the threshold for clinically dominant organic acid competition is typically eGFR well below 30 mL/min/1.73m²; at eGFR 47 mL/min/1.73m², this is not the primary mechanism.
• Option D: Option D is incorrect: while over-the-counter NSAID use should always be investigated, the clinical scenario explicitly confirms no NSAID use on medication review; concluding NSAID use is "likely" despite a negative medication history is not evidence-based reasoning.

ANSWER: C

Rationale:

Sequential nephron blockade is the pharmacological basis for the furosemide-metolazone combination. Furosemide blocks NKCC2 in the thick ascending limb, delivering a large sodium load to the distal nephron. In R.T., the braking phenomenon means that the distal convoluted tubule — hypertrophied and equipped with upregulated NCC — reclaims an increasing fraction of this delivered sodium before it reaches the collecting duct, attenuating net natriuresis. Metolazone is a thiazide-like diuretic that blocks NCC directly in the distal convoluted tubule. Adding metolazone intercepts the sodium at the second reabsorptive barrier — the NCC — that the braking phenomenon has upregulated. With both NKCC2 (loop) and NCC (distal tubule) simultaneously blocked, sodium must traverse both nephron segments without reabsorption until it reaches the collecting duct, where the aldosterone-driven reabsorptive capacity is overwhelmed by the dramatically increased sodium load. The resulting natriuresis is far greater than either drug alone — it is synergistic rather than simply additive, because metolazone specifically targets the adaptive mechanism that was attenuating furosemide's effect. Metolazone retains NCC-blocking efficacy at low eGFR (unlike hydrochlorothiazide, which loses efficacy at eGFR below 30 mL/min/1.73m²), making it the preferred thiazide-like agent for sequential nephron blockade in CKD-complicated HF.

• Option A: Option A is incorrect: metolazone does not inhibit carbonic anhydrase in the proximal tubule; that is the mechanism of acetazolamide; metolazone acts at the distal convoluted tubule NCC.
• Option B: Option B is incorrect: metolazone does not bind an allosteric site on NKCC2 or enhance furosemide's NKCC2 affinity; the two drugs act at entirely distinct nephron segments through distinct transporters.
• Option D: Option D is incorrect: metolazone does not inhibit intestinal P-glycoprotein to increase furosemide bioavailability; this mechanism is fabricated and has no pharmacological basis.
• Option E: Option E is incorrect: metolazone does not inhibit CYP11B2 (aldosterone synthase) or reduce adrenal aldosterone synthesis; it is a direct NCC-blocking diuretic, not an aldosterone synthesis inhibitor.

ANSWER: A

Rationale:

The clinical rule that hypomagnesemia must be corrected before or concurrently with potassium replacement is one of the most practically important bedside principles in electrolyte management. The mechanism: magnesium is an essential cofactor for Na-K-ATPase, the enzyme that maintains intracellular potassium by pumping potassium into cells across the basolateral membrane. When intracellular magnesium is depleted, Na-K-ATPase activity is impaired throughout the body — including in renal tubular principal cells. In principal cells, reduced Na-K-ATPase activity lowers intracellular potassium concentration, which increases the electrochemical driving force for ROMK-mediated potassium secretion from the cell into the tubular lumen. The result is persistent urinary potassium wasting that continues regardless of how much IV potassium is administered — the kidneys simply excrete the replacement as fast as it is given. This is why clinicians observe "refractory hypokalemia" in patients with concurrent hypomagnesemia: the potassium gap cannot be closed until the underlying magnesium deficit is corrected. In R.T., Mg 1.0 mg/dL represents severe hypomagnesemia, and IV magnesium repletion must be started before or simultaneously with IV potassium to achieve durable correction. Additionally, metolazone should be held given the urine output of 350 mL/hour and the electrolyte crisis developing.

• Option B: Option B is incorrect: hyponatremia does not impair Na-K-ATPase in a way that renders potassium replacement ineffective; the mechanism described is pharmacologically inaccurate, and sodium chloride supplementation is not the priority before potassium replacement.
• Option C: Option C is incorrect: while metolazone should be held, IV normal saline 1 liter before electrolyte replacement is not the priority; magnesium repletion is the specific mechanistic priority to enable effective potassium correction, and volume status must be assessed clinically before administering a saline bolus in a patient with HFrEF.
• Option D: Option D is incorrect: IV calcium gluconate is indicated for severe symptomatic hyperkalemia with ECG changes — not for hypokalemia; calcium gluconate does not treat hypokalemia and administering it in this context would be inappropriate.
• Option E: Option E is incorrect: while metabolic alkalosis does shift potassium intracellularly, IV sodium bicarbonate would worsen the alkalosis from aggressive diuresis, not correct it; and the primary refractory mechanism in R.T.'s hypokalemia is the magnesium-ROMK pathway, not the alkalotic shift.

ANSWER: D

Rationale:

Metolazone's potent and unpredictable synergistic natriuretic effect with loop diuretics makes it poorly suited for routine daily chronic outpatient use. The same mechanism that makes it effective — simultaneous blockade of two major nephron sodium reabsorption sites — means that even a single dose can produce dramatic and rapidly evolving electrolyte derangements (severe hypokalemia, hypomagnesemia, hyponatremia) and volume depletion within hours. In an outpatient setting without same-day laboratory monitoring, these derangements can progress to dangerous levels before they are detected. For this reason, the standard of care is that metolazone is reserved for: (1) episodic supervised outpatient use for acute diuretic insufficiency, with same-day or next-day laboratory monitoring (potassium, magnesium, sodium, creatinine) and close clinical follow-up; or (2) in-hospital use where continuous monitoring is available. Between episodes, the goal is to optimize furosemide dosing (increase if appropriate), ensure complete GDMT optimization (MRA continuation reduces aldosterone-driven sodium retention), and use the minimum effective furosemide dose that maintains euvolemia. Some highly motivated patients with reliable follow-up may use a prescribed "as-needed" metolazone protocol for early weight gain (e.g., 1–2 doses with weight gain of 2–3 kg above dry weight, with mandated same-day labs), but this requires careful patient education and accessible laboratory monitoring.

• Option A: Option A is incorrect: the braking phenomenon is not a fully permanent irreversible adaptation — it can partially reverse with reduced furosemide doses or diuretic holidays; and continuous daily metolazone outpatient use is not safe without continuous monitoring.
• Option B: Option B is incorrect: metolazone does have an outpatient role in episodic supervised use — the statement that it has "no role" in outpatient management is an overcorrection.
• Option C: Option C is incorrect: the DOSE trial did not study twice-weekly metolazone as an outpatient regimen; the 34% rehospitalization reduction claim is fabricated, and no AHA/ACC/HFSA standard specifies a twice-weekly metolazone protocol.
• Option E: Option E is incorrect: metolazone at any dose does not block aldosterone at the distal convoluted tubule; its mechanism is direct NCC blockade, not aldosterone antagonism; and a "sub-threshold" metolazone dose for braking prevention is not an established clinical strategy. CASE 3 P.N. is a 58-year-old man with HFrEF (LVEF 32%, NYHA class II) on sacubitril/valsartan 97/103 mg twice daily, carvedilol 25 mg twice daily, and furosemide 40 mg daily. He has not yet been started on an MRA (mineralocorticoid receptor antagonist). Potassium is 4.3 mEq/L and eGFR is 56 mL/min/1.73m².

ANSWER: B

Rationale:

Among the three major MRA trials, EMPHASIS-HF is the most directly applicable to P.N. for two reasons: population match and background therapy match. EMPHASIS-HF enrolled patients with LVEF of 35% or less and NYHA class II symptoms — exactly P.N.'s profile — on contemporary background GDMT including ACE inhibitor or ARB and beta-blocker. P.N. is on an ARNI (sacubitril/valsartan) rather than a standalone ACE inhibitor or ARB, but AHA/ACC/HFSA guidelines support extrapolation of MRA benefit to patients on ARNI-based GDMT: the ARNI provides AT1 (angiotensin type 1) receptor blockade (via valsartan) equivalent to an ARB, and MRA therapy is listed as a class I recommendation in HFrEF patients on ARNI plus beta-blocker when renal function and potassium permit. P.N.'s eGFR of 56 mL/min/1.73m² and potassium of 4.3 mEq/L are both within acceptable thresholds. MRA should be initiated — spironolactone 25 mg or eplerenone 25 mg daily — with potassium and creatinine checked within 1–2 weeks.

• Option A: Option A is incorrect: RALES enrolled NYHA class III–IV patients (not class II) and was conducted before routine beta-blocker use; P.N.'s NYHA class II profile and modern GDMT make EMPHASIS-HF the more directly applicable trial.
• Option C: Option C is incorrect: current AHA/ACC/HFSA guidelines do not restrict MRA initiation to patients specifically on ACE inhibitor or ARB rather than ARNI; the ARNI's valsartan component provides ARB-equivalent RAAS blockade, and the class I MRA recommendation applies to patients on ARNI-based GDMT.
• Option D: Option D is incorrect: EPHESUS enrolled patients specifically in the post-MI LV dysfunction setting (within 3–14 days of MI); P.N. has no post-MI history, and the post-MI context is not "irrelevant" — it defines the EPHESUS population and limits direct applicability to post-MI patients.
• Option E: Option E is incorrect: the strength of a guideline recommendation is based on the totality of evidence, not solely on the type of primary endpoint; EMPHASIS-HF's composite endpoint includes cardiovascular death (a mortality component) and its evidence directly supports the class I recommendation for NYHA class II patients.

ANSWER: E

Rationale:

Spironolactone's gynecomastia is a mechanism-based adverse effect arising from its non-selective receptor binding. Spironolactone and its active metabolites bind androgen receptors as antagonists in addition to blocking the mineralocorticoid receptor. In male breast tissue, androgens normally suppress glandular proliferation; spironolactone's anti-androgenic effect removes this suppression, allowing estrogen-driven glandular growth — producing true gynecomastia (glandular tissue enlargement) and tenderness. This was confirmed in RALES, where gynecomastia or breast tenderness occurred in approximately 10% of men on spironolactone versus approximately 1% on placebo. Because the mechanism is receptor-binding at therapeutic concentrations, dose reduction often does not fully eliminate the side effect. The correct response is to switch to eplerenone, which was structurally modified to achieve high MR selectivity with minimal androgen receptor and progesterone receptor affinity — producing endocrine side effects comparable to placebo in clinical trials. P.N.'s GDMT indication remains strong (NYHA class II, LVEF 32%, EMPHASIS-HF population) and MRA therapy should be continued with eplerenone.

• Option A: Option A is incorrect: canrenone is not a direct estrogen receptor agonist; gynecomastia is produced by androgen receptor antagonism, not estrogen receptor agonism, and dose reduction is not reliably effective for receptor-mediated gynecomastia.
• Option B: Option B is incorrect: spironolactone does not inhibit CYP19A1 (aromatase); its gynecomastia is from androgen receptor blockade, not aromatase inhibition; eplerenone does resolve the problem because its structural modification eliminates androgen receptor activity.
• Option D: Option D is incorrect: AHA/ACC/HFSA guidelines do not classify gynecomastia as an acceptable class I adverse event precluding substitution; they explicitly support switching to eplerenone when spironolactone-induced endocrine side effects are intolerable.

ANSWER: C

Rationale:

Eplerenone shares spironolactone's fundamental pharmacodynamic mechanism at the mineralocorticoid receptor in the collecting duct — competitive MR blockade reduces aldosterone-driven transcriptional upregulation of ENaC and Na-K-ATPase, reducing sodium reabsorption and potassium excretion. This means eplerenone carries the same risk of hyperkalemia and renal function change as spironolactone; it is not "safer" with respect to renal potassium handling. The monitoring requirement — potassium and creatinine within 1–2 weeks of initiation and after any dose change — is identical for both agents. What eplerenone eliminates is the endocrine side effect profile: its minimal androgen and progesterone receptor affinity means no gynecomastia, no breast tenderness, and no menstrual irregularities. For P.N. on sacubitril/valsartan, the valsartan component provides AT1 receptor blockade that reduces angiotensin II-stimulated aldosterone secretion; eplerenone then blocks aldosterone action at the MR; together they additively reduce collecting duct potassium excretion, making close monitoring particularly important. Option B is correct in content and is a good answer, but Option C is more complete — it specifically addresses the additive potassium-retaining interaction with sacubitril/valsartan that is directly relevant to P.N.'s regimen, making C the most comprehensive and precise response.

• Option A: Option A is incorrect: eplerenone absolutely requires hyperkalemia and renal function monitoring; MR blockade in the kidney reduces potassium excretion regardless of whether the agent also binds androgen or progesterone receptors — selectivity does not eliminate the renal pharmacodynamic effect.
• Option D: Option D is incorrect: eplerenone does not have higher MR binding affinity than spironolactone — spironolactone generally has somewhat greater MR affinity, which is one reason higher eplerenone doses may be needed; daily monitoring is not mandated by AHA/ACC/HFSA guidelines for patients on ARNI plus eplerenone.
• Option E: Option E is incorrect: eplerenone's onset of MR blockade is not substantially slower than spironolactone's; monitoring at 1 week is clinically important and is the standard recommendation after MRA initiation in patients on combination RAAS therapy.

ANSWER: A

Rationale:

A confirmed potassium of 5.2 mEq/L in an asymptomatic patient with a normal ECG warrants a structured stepwise response aimed at preserving eplerenone therapy rather than simply discontinuing it. The approach mirrors the standard hyperkalemia management protocol: (1) Confirm the result — hemolysis or delayed specimen processing can falsely elevate potassium; (2) Review contributing factors — dietary potassium intake, potassium supplements, drugs that impair renal potassium excretion (trimethoprim acts like amiloride on ENaC and can raise potassium significantly), and over-the-counter NSAIDs; (3) Reduce or temporarily hold eplerenone to lower the acute potassium burden; (4) Consider a potassium binder — patiromer or SZC have clinical trial evidence (AMBER trial for patiromer in CKD, DIAMOND trial for patiromer enabling MRA therapy in HFrEF) supporting their use to enable MRA continuation in patients who develop hyperkalemia; (5) Recheck potassium within 1 week with the target below 5.0 mEq/L before resuming or up-titrating eplerenone. This approach preserves P.N.'s class I GDMT indication (NYHA class II HFrEF, EMPHASIS-HF population) while managing the electrolyte risk through a combination of dose adjustment and binder therapy if needed.

• Option B: Option B is incorrect: a potassium of 5.2 mEq/L with eGFR 52 mL/min/1.73m² is not an absolute permanent contraindication to MRA therapy; this is the threshold for dose reduction and monitoring, not permanent discontinuation — particularly in a patient with a well-established GDMT indication.
• Option C: Option C is incorrect: increasing eplerenone to 50 mg in the setting of hyperkalemia is the opposite of the correct response; MR blockade reduces potassium excretion, so increasing the dose would worsen the hyperkalemia, not stabilize it.
• Option D: Option D is incorrect: adding an ACE inhibitor (lisinopril) to sacubitril/valsartan is contraindicated; the combination of an ARNI plus an ACE inhibitor is contraindicated due to risk of angioedema and excessive hypotension; it would also further reduce aldosterone secretion and worsen hyperkalemia.
• Option E: Option E is incorrect: spironolactone does not have a lower potassium-retaining effect than eplerenone; canrenone is a full MR antagonist, not a partial agonist; switching to spironolactone in a man who already developed gynecomastia on spironolactone would be inappropriate. CASE 4 S.K. is a 61-year-old man admitted 9 days ago for an anterior STEMI (ST-elevation myocardial infarction) treated with primary PCI (percutaneous coronary intervention). His post-MI echocardiogram shows LVEF 34% with anterior hypokinesis. He has mild dyspnea on exertion. Current medications: aspirin, ticagrelor, atorvastatin, ramipril 5 mg daily, and metoprolol succinate 25 mg daily. Potassium is 4.5 mEq/L and creatinine is 1.0 mg/dL (eGFR 74 mL/min/1.73m²). He does not have diabetes.

ANSWER: D

Rationale:

EPHESUS (Pitt et al., N Engl J Med, 2003) enrolled patients with acute MI complicated by LV dysfunction (LVEF of 40% or less) and either symptomatic heart failure or diabetes mellitus — these were disjunctive (either/or) enrollment criteria, not conjunctive (both required). Randomization occurred 3–14 days post-MI on background ACE inhibitor and beta-blocker therapy. S.K. satisfies every criterion precisely: LVEF 34% (at or below 40%), dyspnea on exertion (symptomatic HF), day 9 post-MI (within the 3–14 day window), on ramipril (ACE inhibitor) and metoprolol succinate (beta-blocker), potassium 4.5 mEq/L (below 5.0 mEq/L), and eGFR 74 mL/min/1.73m² (well above 30 mL/min/1.73m²). The EPHESUS initiation protocol started eplerenone at 25 mg daily, with titration to 50 mg at 4 weeks if potassium remained below 5.0 mEq/L. This stepwise approach is the evidence-based standard for post-MI eplerenone initiation. Potassium and creatinine should be rechecked within 1 week given the combined RAAS blockade of ramipril and eplerenone.

• Option A: Option A is incorrect: EPHESUS used LVEF of 40% or less as the enrollment threshold (not 30% or less); S.K.'s LVEF of 34% is within the eligible range.
• Option B: Option B is incorrect: EPHESUS required either symptomatic HF or diabetes — not both; S.K.'s symptomatic HF alone satisfies the enrollment criterion.
• Option C: Option C is incorrect: the EPHESUS protocol initiated eplerenone at 25 mg daily (not the target 50 mg dose); starting at the target dose in a post-MI patient on dual RAAS blockade increases acute hyperkalemia risk.
• Option E: Option E is incorrect: the EPHESUS benefit was demonstrated with enrollment at 3–14 days post-MI; there is no per-protocol finding of harm with early initiation within 14 days, and no post-EPHESUS guidance recommends deferring to day 30.

ANSWER: B

Rationale:

The EPHESUS protocol specified a clear titration decision rule: if potassium was below 5.0 mEq/L at 4 weeks and the patient was hemodynamically stable, eplerenone was increased from 25 mg to 50 mg daily — the pre-specified target dose. S.K.'s potassium of 4.8 mEq/L is below the 5.0 mEq/L threshold, his creatinine is stable, and he is asymptomatic, meeting all criteria for dose titration. The rationale for reaching the 50 mg target dose is that EPHESUS demonstrated mortality benefit with eplerenone titrated to 50 mg daily — the trial was not powered to assess the benefit of the 25 mg starting dose independently, and the target dose is the one with the established survival benefit. Importantly, any dose increase requires close monitoring: potassium and creatinine should be rechecked within 1 week of the dose increase given the additive potassium-retaining effects of eplerenone (MR blockade reducing collecting duct potassium excretion) and ramipril (ACE inhibition reducing angiotensin II-driven aldosterone secretion).

• Option A: Option A is incorrect: there is no EPHESUS protocol 4.5 mEq/L titration threshold or 25% hyperkalemia probability estimate; the EPHESUS titration criterion was potassium below 5.0 mEq/L at 4 weeks — S.K. meets this criterion.
• Option C: Option C is incorrect: laboratory monitoring after dose increase is mandatory, not optional; dose escalation with combined RAAS blockade requires potassium and creatinine recheck within approximately 1 week.
• Option D: Option D is incorrect: a rise from 4.5 mEq/L to 4.8 mEq/L over 4 weeks is a modest change that remains below the 5.0 mEq/L threshold for dose maintenance and titration; there is no standard recommendation to reduce the eplerenone dose for a 0.3 mEq/L potassium increase within the normal range.
• Option E: Option E is incorrect: eplerenone's dose-response for MR blockade does not plateau at 25 mg in patients with eGFR below 75 mL/min/1.73m²; this is a fabricated pharmacokinetic claim; and switching to spironolactone in a post-MI patient whose original indication is EPHESUS-based would substitute an agent without the specific post-MI evidence base.

ANSWER: E

Rationale:

K⁺ 5.6 mEq/L with peaked T waves on ECG represents symptomatic hyperkalemia with ECG evidence of membrane instability — this is an urgent management situation requiring immediate treatment, not watchful waiting or oral binder alone. The management sequence follows established principles: (1) IV calcium gluconate is the immediate first step — it stabilizes the cardiac membrane by raising the threshold potential, protecting against arrhythmia while other interventions lower the potassium concentration; calcium does not lower serum potassium but acts within minutes to protect the heart. (2) Temporizing measures to shift potassium intracellularly: insulin (10 units IV) with dextrose (25–50 g) shifts K⁺ into cells within 30–60 minutes; sodium bicarbonate helps in the presence of metabolic acidosis; salbutamol (albuterol) via nebulizer activates beta-2 receptors and shifts potassium intracellularly. (3) Remove potassium: loop diuretic (if volume status allows) increases urinary potassium excretion; oral or rectal patiromer or SZC for sustained GI potassium removal. (4) Hold the causative agents: eplerenone and ramipril both contribute to potassium retention and should be held during the acute episode. (5) Reassess GDMT: once the acute episode is resolved, the plan for re-introducing MRA with a potassium binder to prevent recurrence should be discussed.

• Option A: Option A is incorrect: peaked T waves with K⁺ 5.6 mEq/L require IV calcium gluconate as an immediate first step — oral patiromer alone takes hours to lower potassium and provides no protection against arrhythmia during the intervening period.
• Option B: Option B is incorrect: peaked T waves in this setting are not a normal variant; they are a recognized ECG manifestation of hyperkalemia indicating cardiac membrane instability, and a single missed eplerenone dose will not produce rapid potassium normalization.
• Option C: Option C describes the correct management sequence for the most part, but omits the step of rechecking ECG and potassium after acute management and does not mention SZC as an alternative binder — Option E is the more complete and precisely sequenced answer.
• Option D: Option D is incorrect: peaked T waves from hyperkalemia are not an indication for cardioversion; peaked T waves represent early repolarization abnormality, not a shockable rhythm; cardioversion would be inappropriate and potentially harmful.

ANSWER: C

Rationale:

The strategy of using a potassium binder to enable MRA re-initiation after a hyperkalemic episode represents one of the most important advances in GDMT optimization for patients with CKD and HFrEF. Patiromer and SZC are novel potassium binders with favorable tolerability profiles that reduce serum potassium by binding potassium in the gastrointestinal tract. The DIAMOND trial (Patiromer for Cardiorenal Risk Reduction in Patients with Resistant Hypertension and CKD, with MRA-enabling as a secondary application in HFrEF) demonstrated that patiromer enables MRA dose maintenance and re-titration in patients who would otherwise require permanent discontinuation due to hyperkalemia. The clinical strategy for S.K.: initiate the potassium binder first to establish a lower baseline potassium before reintroducing eplerenone; once potassium is controlled below 4.5 mEq/L on the binder, restart eplerenone at 25 mg daily (not the prior 50 mg — restart from the lowest available dose given the documented tolerance issue); recheck potassium within 1 week; if tolerated with stable potassium, titrate back toward 50 mg with sustained binder therapy. This approach preserves S.K.'s EPHESUS-supported survival benefit from eplerenone — a post-MI class I GDMT indication — while managing the electrolyte risk.

• Option A: Option A is incorrect: AHA/ACC/HFSA guidelines do not impose a 12-month MRA ban after ECG-confirmed hyperkalemia; the potassium binder strategy exists specifically to enable MRA continuation and re-initiation in such patients.
• Option B: Option B is incorrect: restarting eplerenone without a potassium binder or further electrolyte management after a hyperkalemic ECG-change episode is not appropriate; dietary restriction to 2 g potassium daily alone is insufficient to prevent recurrence in a patient on dual RAAS blockade with eGFR above baseline CKD.
• Option D: Option D is incorrect: AHA/ACC/HFSA guidelines do not mandate a sequential RAAS re-introduction protocol with 2-week intervals; and 12.5 mg eplerenone dosing is not a standard formulation.
• Option E: Option E is incorrect: replacing ramipril with hydralazine-isosorbide dinitrate is a last resort for patients who genuinely cannot tolerate any RAAS inhibitor; it removes the neurohormonal survival benefit of ACE inhibition in a post-MI patient without justification; and the claim that eplerenone alone will not produce hyperkalemia without concurrent RAAS inhibition is incorrect — MR blockade reduces potassium excretion independently of ACE inhibitor-mediated aldosterone suppression. CASE 5 L.B. is a 69-year-old woman with HFrEF (LVEF 26%, NYHA class III) admitted with acute decompensation. She receives IV furosemide at 2.5× her oral daily dose. At 48 hours she has lost only 1.5 kg; JVP remains elevated at 13 cm H₂O; urine output averages 65 mL/hour; and creatinine has risen modestly from 1.0 to 1.2 mg/dL. Blood pressure is stable. Her cardiologist considers adding IV acetazolamide 500 mg daily.

ANSWER: A

Rationale:

Acetazolamide's mechanism and the ADVOR trial evidence are the key elements this question tests. Acetazolamide inhibits carbonic anhydrase in proximal tubular cells, impairing the conversion of carbonic acid to CO₂ and water that is coupled to NHE3-driven sodium-hydrogen exchange. Blocking this step reduces bicarbonate reabsorption and the coupled sodium reabsorption in the proximal tubule, delivering additional sodium to the loop of Henle. This sodium arrives at NKCC2 already in the tubular lumen where furosemide's NKCC2 blockade operates — the two drugs act through mechanistically distinct and geographically sequential sites (proximal tubule for acetazolamide; loop of Henle for furosemide) and produce complementary rather than redundant natriuresis. The ADVOR trial randomized 519 patients with acute decompensated HF and signs of volume overload on background standardized IV loop diuretic therapy to IV acetazolamide 500 mg daily versus placebo. Primary endpoint: successful decongestion (absence of signs of volume overload) at 3 days — 42.2% acetazolamide versus 30.5% placebo (RR 1.46; p<0.001). No significant difference in 3-month mortality. For L.B., who is failing standard high-dose furosemide, adding acetazolamide is the ADVOR-supported next step before escalating to sequential nephron blockade with metolazone.

• Option B: Option B is incorrect: acetazolamide does not act on NKCC2; it acts in the proximal tubule via carbonic anhydrase inhibition; and ADVOR did not demonstrate a 22% mortality reduction.
• Option C: Option C is incorrect: acetazolamide does not inhibit aldosterone synthesis or act on the adrenal cortex; it inhibits renal tubular carbonic anhydrase; and ADVOR's benefit was not restricted to patients with elevated baseline aldosterone.
• Option D: Option D is incorrect: acetazolamide does not inhibit SGLT2 and does not produce osmotic glucosuria; its mechanism is carbonic anhydrase inhibition; and ADVOR did not show a 90-day hospitalization reduction.
• Option E: Option E is incorrect: acetazolamide's benefit in ADVOR is not mediated by renal vasodilation or enhanced OAT1/OAT3 furosemide delivery; the mechanism is proximal tubule sodium delivery augmentation through carbonic anhydrase inhibition.

ANSWER: D

Rationale:

The blood gas shows pH 7.50 (alkalosis), PCO₂ 50 mmHg (elevated — respiratory compensation by CO₂ retention), and bicarbonate 38 mEq/L (markedly elevated) — this is a primary metabolic alkalosis with appropriate respiratory compensation. Aggressive loop diuretic therapy, now augmented by acetazolamide's proximal sodium delivery, generates metabolic alkalosis through two well-established mechanisms: (1) Urinary chloride wasting — furosemide's NKCC2 blockade delivers large chloride loads to the distal nephron; urinary chloride excretion exceeds intake, reducing serum chloride; because electrical neutrality must be maintained in the extracellular fluid, bicarbonate (the major alternative anion) accumulates as chloride falls — shifting the bicarbonate-chloride equilibrium toward bicarbonate retention. (2) Volume contraction alkalosis — aggressive diuresis reduces extracellular fluid volume, activating the renin-angiotensin-aldosterone system; aldosterone stimulates both distal sodium reabsorption and H⁺ secretion (via H-ATPase in intercalated cells), generating new bicarbonate; volume contraction also increases fractional bicarbonate reabsorption in the proximal tubule. While acetazolamide itself inhibits proximal bicarbonate reabsorption (an alkalosis-preventing effect), the net result with high-dose furosemide dominates toward alkalosis from chloride wasting and volume contraction. The appropriate respiratory compensation: for every 1 mEq/L rise in bicarbonate above 24, PCO₂ is expected to rise approximately 0.7 mmHg — a bicarbonate of 38 mEq/L (14 mEq/L above normal) predicts PCO₂ compensation of approximately 24 + 0.7×14 ≈ 34 mmHg above 40, giving expected PCO₂ ≈ 50 mmHg — exactly what L.B. shows, confirming pure metabolic alkalosis with appropriate compensation. Management: reassess diuretic intensity as she approaches euvolemia; ensure potassium chloride supplementation (chloride repletion is essential for correcting contraction alkalosis).

• Option A: Option A is incorrect: furosemide does not impair CO₂ excretion by binding carbonic anhydrase co-expressed with NKCC2 — this is a fabricated mechanism; the pH 7.50 indicates alkalosis, not acidosis.
• Option B: Option B is incorrect: acetazolamide does inhibit bicarbonate reabsorption, which would generate metabolic acidosis in isolation, but the dominant acid-base effect with high-dose furosemide and aggressive diuresis is metabolic alkalosis — the pH confirms alkalosis, not acidosis.
• Option C: Option C is incorrect: furosemide does not stimulate the respiratory center via prostaglandin release to produce respiratory alkalosis; the respiratory changes are compensatory, not primary; and propranolol is not a treatment for this acid-base disturbance.
• Option E: Option E is incorrect: the PCO₂ of 50 mmHg is elevated (not reduced), indicating CO₂ retention as metabolic alkalosis compensation, not primary respiratory alkalosis from hyperventilation; the description inverts the expected findings.

ANSWER: B

Rationale:

The discharge diuretic strategy requires addressing two questions: which agent(s) to use, and at what dose. For the agent question: IV acetazolamide is an acute inpatient therapy that augments loop diuretic response during hospitalization. The ADVOR trial studied IV acetazolamide added to background IV loop diuretic in hospitalized patients with acute decompensation — it did not study oral acetazolamide as a chronic outpatient maintenance agent, and there is no established evidence base for prescribing oral acetazolamide as an outpatient diuretic in HFrEF. Acetazolamide also generates metabolic alkalosis risk with prolonged use, as was observed in L.B. For the outpatient loop diuretic, torsemide is a pharmacokinetically superior choice (oral bioavailability 80–90% vs. furosemide's variable 10–100%) and is the appropriate oral loop diuretic for maintenance. The dose should reflect the effective IV dose used during hospitalization — typically the IV dose that achieved euvolemia converted to oral equivalent (IV furosemide dose × 2 for oral furosemide, or converted to torsemide using the standard potency ratio).

• Option A: Option A is incorrect: ADVOR did not establish chronic oral acetazolamide as a long-term outpatient diuretic regimen; the trial was conducted with IV acetazolamide in the inpatient setting and did not include an outpatient maintenance phase.
• Option C: Option C is incorrect: there is no AHA/ACC/HFSA protocol specifying that outpatient maintenance dose is universally half the admission dose; the discharge dose should reflect the patient's actual effective inpatient diuretic requirement and dry weight target.
• Option D: Option D is incorrect: acetazolamide monotherapy is not an established chronic outpatient diuretic strategy in HFrEF, and ADVOR did not compare acetazolamide monotherapy to furosemide.
• Option E: Option E is incorrect: TRANSFORM-HF did not demonstrate significant mortality reduction with torsemide compared to furosemide (HR 1.02; p=0.82), and AHA/ACC/HFSA guidelines do not give torsemide a class I recommendation over furosemide based on mortality evidence.

ANSWER: E

Rationale:

Synthesizing DOSE and ADVOR into a rational escalation sequence requires accurately applying what each trial demonstrated and what it did not. DOSE established: (1) high-dose IV furosemide (2.5× oral dose) is superior to low-dose for decongestion; (2) continuous infusion is NOT superior to bolus dosing — so switching to infusion when standard bolus high-dose fails has no evidence of benefit. ADVOR established: adding IV acetazolamide 500 mg daily to background IV loop diuretic therapy significantly improves decongestion at 3 days compared to placebo (RR 1.46; p<0.001), acting through a mechanistically distinct proximal tubule site. The rational sequence for a patient failing 2.5× bolus furosemide: first, confirm the dose is actually at the DOSE-established 2.5× level and delivered as bolus (continuous infusion offers no incremental benefit); second, add acetazolamide per ADVOR as the next mechanistically justified step; third, if still inadequate, add metolazone to overcome the braking phenomenon or CKD-related distal sodium reclamation through sequential nephron blockade. Each step should be assessed before adding the next — this avoids unnecessary polypharmacy and allows attribution of response to each intervention.

• Option A: Option A is incorrect: DOSE did not demonstrate superiority of continuous infusion over bolus dosing; switching to continuous infusion when bolus high-dose fails has no evidence base and would not be the first escalation step.
• Option B: Option B is incorrect: DOSE did not establish a 5× oral dose as a safe or superior escalation strategy; the high-dose arm was specifically 2.5× the oral dose, and escalation beyond this point was not studied.
• Option C: Option C is incorrect: DOSE and ADVOR did not restrict enrollment to specific eGFR ranges that prevent synthesis; DOSE enrolled general acute decompensated HF patients and ADVOR enrolled patients with volume overload on background loop diuretic without an eGFR cutoff separating the two trials' populations.
• Option D: Option D is incorrect: switching from furosemide to bumetanide is not an established escalation step for furosemide resistance; the two drugs act through the same NKCC2 mechanism and a simple drug switch does not address the underlying resistance mechanism. CASE 6 F.M. is a 71-year-old woman with HFpEF (LVEF 58%, NYHA class II, hospitalized for HF 6 months ago). She is on furosemide 40 mg daily, empagliflozin 10 mg daily, and metoprolol succinate 25 mg daily. Her potassium is 4.4 mEq/L and eGFR is 54 mL/min/1.73m². Her cardiologist discusses initiating spironolactone.

ANSWER: C

Rationale:

The evidence base for spironolactone in HFpEF is genuinely uncertain and the guideline recommendation reflects that uncertainty. TOPCAT (Pitt et al., N Engl J Med, 2014) enrolled 3,445 patients with HFpEF (LVEF 45% or greater) and did not meet its primary composite endpoint overall (HR 0.89; 95% CI 0.77–1.04; p=0.14). The trial is methodologically controversial: post-hoc pharmacokinetic analyses found near-zero plasma canrenone concentrations in patients from Russia and Georgia, suggesting those patients may not have received active spironolactone; Americas subgroup analyses show a significant reduction in HF hospitalization. The appropriate guideline response to uncertain evidence is a class IIb recommendation — meaning the therapy "may be reasonable to consider" — which is exactly what AHA/ACC/HFSA 2022 guidelines assign for MRAs in symptomatic HFpEF. F.M. has a prior hospitalization (one of the TOPCAT enrollment pathways) and acceptable renal function and potassium, making her a reasonable class IIb candidate. Shared decision-making is appropriate given the uncertain evidence.

• Option A: Option A is incorrect: TOPCAT's overall primary endpoint did not reach statistical significance; there is no class I recommendation based on TOPCAT, and the Americas subgroup analysis is hypothesis-generating, not confirmatory.
• Option B: Option B is incorrect: TOPCAT enrolled patients with LVEF 45% or greater — there is no upper LVEF limit of 55%; F.M.'s LVEF of 58% falls within the enrolled range.
• Option D: Option D is incorrect: spironolactone and empagliflozin are not contraindicated in combination; they have complementary mechanisms and potentially favorable potassium interactions (SGLT2 inhibitors modestly lower potassium, partially offsetting MRA-driven potassium retention); no guideline recommends using only one class or the other in HFpEF.
• Option E: Option E is incorrect: no current AHA/ACC/HFSA guideline specifies stopping an SGLT2 inhibitor before adding an MRA in HFpEF; the two drug classes can be combined.

ANSWER: A

Rationale:

The 0.3 mEq/L potassium rise at 2 weeks reflects the expected pharmacodynamic consequence of MR blockade: spironolactone blocks aldosterone-driven upregulation of ENaC and Na-K-ATPase in collecting duct principal cells, reducing the electrochemical gradient for collecting duct potassium secretion and thereby reducing urinary potassium excretion. The rise to 4.7 mEq/L is modest and does not exceed the 5.0 mEq/L threshold requiring action. The mechanistically important point for this question is the potassium-modifying effect of empagliflozin. SGLT2 inhibition in the proximal tubule blocks glucose-coupled sodium reabsorption, increasing the sodium load delivered to distal nephron segments including the collecting duct; the increased distal tubular sodium delivery augments Na-K exchange in principal cells, mildly increasing potassium secretion into the tubular lumen. Clinical trial data from EMPEROR-Reduced (empagliflozin) and DAPA-HF (dapagliflozin) in HFrEF — and supported by mechanistic reasoning in HFpEF — demonstrate that SGLT2 inhibitors are associated with significantly lower rates of hyperkalemia compared to placebo, including in patients on MRA therapy. This makes empagliflozin a pharmacologically favorable co-medication in F.M.'s regimen, partially mitigating the potassium-retaining effect of spironolactone. The 4.7 mEq/L value warrants continued monitoring but does not require dose reduction.

• Option B: Option B is incorrect: a potassium of 4.7 mEq/L is within the acceptable range and does not trigger mandatory dose reduction; there is no 4.5 mEq/L ceiling mandating dose adjustment within the first 4 weeks.
• Option C: Option C is incorrect: SGLT2 inhibitors do not block SGLT2-mediated potassium cotransport — there is no glucose-potassium cotransport pathway in SGLT2; SGLT2 inhibitors increase potassium excretion by increasing distal sodium delivery, not reduce it; the "multiplicative" hyperkalemia risk is the opposite of the clinical evidence.
• Option D: Option D is incorrect: the potassium rise reflects MRA pharmacodynamics, not furosemide-induced GFR reduction; reducing furosemide would worsen volume status in a patient with HFpEF and is not indicated for potassium management.
• Option E: Option E is incorrect: while the potassium of 4.7 mEq/L is acceptable, describing this as a "perfect balance" requiring no future monitoring oversimplifies the management — the value warrants continued monitoring at regular intervals, not a declaration of stable equilibrium.

ANSWER: D

Rationale:

Spironolactone's menstrual irregularities in premenopausal and perimenopausal women are a well-established mechanism-based adverse effect arising from its non-selective receptor binding. In addition to the mineralocorticoid receptor, spironolactone and its active metabolites bind progesterone receptors — acting as a partial agonist/antagonist at progesterone receptors in various tissues. Progesterone receptor activity in the hypothalamic-pituitary-ovarian axis disrupts the hormonal signaling required for normal menstrual cycle regulation, producing irregularities including changes in cycle length, flow, and timing. This mechanism is distinct from (though sometimes overlapping with) the anti-androgenic effects through androgen receptor binding. The temporal correlation in F.M. — onset 6 weeks after spironolactone initiation — is mechanistically consistent with a spironolactone-driven change superimposed on her perimenopausal baseline. The correct management is to switch to eplerenone, which was structurally designed to have high MR selectivity with minimal progesterone receptor and androgen receptor affinity; clinical data confirm eplerenone produces menstrual irregularities at rates comparable to placebo. F.M.'s HFpEF indication (class IIb) remains, and preserving MRA therapy by switching to eplerenone is appropriate.

• Option A: Option A is incorrect: spironolactone does not block dopamine D2 receptors and does not cause hyperprolactinemia through this mechanism; menstrual irregularities from spironolactone are progesterone and androgen receptor-mediated, not dopaminergic.
• Option B: Option B is incorrect: spironolactone does not inhibit aromatase (CYP19A1); menstrual irregularities are from direct progesterone receptor binding; eplerenone does not inhibit aromatase and does resolve the problem.
• Option C: Option C is incorrect: while spironolactone does have anti-androgenic effects, the primary mechanism for menstrual irregularities is progesterone receptor binding disrupting hypothalamic-pituitary-ovarian signaling, not hypothalamic androgen receptor blockade specifically reducing GnRH pulsatility as described.
• Option E: Option E is incorrect: temporal correlation (symptoms beginning 6 weeks after initiation in a woman with a stable prior irregular pattern) is clinically meaningful; dismissing a temporally plausible drug-induced effect as coincidental perimenopause without a medication trial is not appropriate clinical reasoning, particularly when a safer alternative (eplerenone) is available.

ANSWER: B

Rationale:

Honest communication about the uncertainty of evidence is as important a clinical skill as the pharmacology itself. The evidence for MRA therapy in HFpEF is genuinely uncertain: TOPCAT's overall primary endpoint (cardiovascular death, aborted cardiac arrest, or HF hospitalization) did not reach statistical significance (HR 0.89; p=0.14); the trial has significant methodological controversy due to suspected non-adherence in Russia and Georgia (near-zero canrenone metabolite concentrations); Americas subgroup analyses suggest benefit in HF hospitalization reduction, but these are post-hoc and cannot replace a pre-specified primary endpoint result. Current AHA/ACC/HFSA 2022 guidelines give MRAs a class IIb recommendation in symptomatic HFpEF — "may be reasonable" — not a class I recommendation. The appropriate patient communication is transparent: explain the uncertain evidence, acknowledge the signal from the Americas data, confirm the class IIb recommendation means it is reasonable to try given her acceptable renal function and potassium, and commit to monitoring and continuing only if well tolerated. Overstating the evidence with a "yes, this will keep you out of the hospital" answer would be inaccurate and potentially misleading.

• Option A: Option A is incorrect: EMPHASIS-HF enrolled HFrEF patients with LVEF below 35% — not HFpEF; its results cannot be directly applied to F.M., and MR-mediated anti-fibrotic benefit does not guarantee equivalent clinical outcomes across different HF phenotypes.
• Option C: Option C is incorrect: the Americas subgroup result is post-hoc and hypothesis-generating, not confirmatory; presenting it as class I evidence or claiming direct applicability of spironolactone TOPCAT data to eplerenone overstates the certainty.
• Option D: Option D is incorrect: TOPCAT did not demonstrate a statistically significant trend toward harm overall; the HR was 0.89 (trending toward benefit, not harm); and eplerenone can reasonably be used in HFpEF based on the same MR-blocking mechanism as spironolactone — no guideline restricts class IIb evidence to spironolactone only.
• Option E: Option E is incorrect: there is no pre-specified hospitalization subgroup analysis of TOPCAT that provides a class I recommendation for patients with prior hospitalization; the recommendation is class IIb regardless of hospitalization history. CASE 7 W.J. is a 76-year-old man with HFrEF (LVEF 25%) admitted for acute decompensation. He is started on IV furosemide at 2.5× his oral daily dose. Over 4 days he loses 7 kg. On day 5, his nurse reports: JVP flat (3 cm H₂O), blood pressure has dropped from 122/74 mmHg (admission) to 92/58 mmHg supine, his extremities are cool, urine output is 12 mL/hour, and creatinine has risen from 1.1 to 2.1 mg/dL (from 1.4 mg/dL yesterday).

ANSWER: E

Rationale:

W.J.'s clinical picture has every feature of true intravascular volume depletion from over-diuresis — the opposite of the hemodynamically stable, still-congested patient in whom acceptable WRF is an appropriate designation. The distinguishing features are definitive: flat JVP at 3 cm H₂O (well below the normal 6–8 cm H₂O — indicating venous filling has been depleted below euvolemia, not achieved euvolemia); supine hypotension at 92/58 mmHg (this is not orthostatic — it is frank supine hypotension indicating inadequate effective circulating volume even lying flat); cool extremities (indicating reduced peripheral perfusion from low cardiac output driven by inadequate preload); and oliguria of 12 mL/hour (renal hypoperfusion from inadequate perfusion pressure). The creatinine rise of 0.7 mg/dL in a single 24-hour period — now totaling 1.0 mg/dL above baseline — is a marker of acute renal ischemia, not acceptable WRF. Acceptable WRF occurs when: creatinine rises modestly in a patient who remains congested, hemodynamically stable, with adequate urine output, warm extremities, and preserved blood pressure. W.J. meets none of these criteria. Continuing IV furosemide at this point risks acute tubular necrosis, severe hemodynamic deterioration, and potentially fatal arrhythmia from worsened perfusion of an already severely impaired myocardium. The furosemide must be stopped and hemodynamics reassessed — this may include careful small fluid challenges if true volume depletion is confirmed, or evaluation for cardiogenic shock requiring inotropic support.

• Option A: Option A is incorrect: the DOSE trial demonstrated that the modest creatinine rise during high-dose diuresis in a hemodynamically stable patient does not worsen outcomes — this finding does not apply to a patient with flat JVP, supine hypotension, cool extremities, and oliguria, which represent a categorically different clinical situation.
• Option B: Option B is incorrect: JVP of 3 cm H₂O is below normal, not within the normal range of 6–8 cm H₂O; this indicates over-diuresis to below euvolemia.
• Option C: Option C is incorrect: bedside pulmonary artery catheterization is not mandatory before stopping furosemide in a patient with frank supine hypotension, flat JVP, cool extremities, and oliguria — the clinical diagnosis of over-diuresis is sufficiently clear to mandate immediate diuretic cessation; delaying for catheterization in this setting is potentially harmful.
• Option D: Option D is incorrect: adding dobutamine while continuing furosemide in a patient with volume depletion (flat JVP, hypotension from inadequate preload) would provide positive inotropy but no volume; in this preload-depleted state, restoring effective circulating volume (by stopping furosemide and reassessing) takes priority over adding inotropes.

ANSWER: A

Rationale:

The management of W.J. after stopping furosemide requires disciplined assessment rather than reflexive intervention. The first priority is holding spironolactone: the combination of acutely worsened renal function (creatinine 2.1 mg/dL) and potassium already at 5.1 mEq/L in a patient whose MRA is contributing to potassium retention creates substantial hyperkalemia risk — particularly since spironolactone's ongoing MR blockade continues reducing collecting duct potassium excretion when renal perfusion is already compromised. The second priority is careful clinical volume status reassessment: distinguishing between (1) true over-diuresis with adequate cardiac output requiring cautious small fluid repletion to restore preload, and (2) cardiogenic low-output state (in which the hypotension reflects pump failure rather than volume depletion, and fluid administration would worsen pulmonary congestion). In W.J. with LVEF 25%, the distinction matters enormously: administering fluids in a low-output cardiogenic state would be harmful. Clinical reassessment — JVP, heart sounds (S3), skin turgor, response to passive leg raise — guides the decision. Cautious small-volume fluid challenge (250 mL over 30 minutes with close monitoring) may be appropriate if true volume depletion is confirmed; inotropic support is required if cardiogenic physiology is operative.

• Option B: Option B is incorrect: aggressive 1-liter IV saline over 30 minutes is inappropriate in a patient with LVEF 25% and a history of severe HFrEF; large-volume resuscitation risks precipitating acute pulmonary edema in a patient with impaired ventricular compliance.
• Option C: Option C is incorrect: restarting furosemide at any dose in a patient with flat JVP, supine hypotension, cool extremities, and oliguria is contraindicated — continuing diuresis in this state would worsen the already inadequate effective circulating volume.
• Option D: Option D is incorrect: the ROSE-AHF trial specifically found that low-dose dopamine did not improve renal function or decongestion compared to placebo in acute decompensated HF — this intervention has negative trial evidence and is not the preferred management for oliguria in this setting.
• Option E: Option E is incorrect: while right heart catheterization may be considered if the clinical picture remains unclear after initial assessment, it is not the first step before any therapeutic decision; holding spironolactone, reassessing volume status, and monitoring electrolytes and ECG are immediate priorities that do not require invasive hemodynamic assessment.

ANSWER: B

Rationale:

The decision to restart diuresis in W.J. requires careful sequencing of clinical and laboratory reassessment before reintroducing a diuretic that recently produced life-threatening hemodynamic compromise. The principles governing the restart decision are: (1) potassium must return to a safer level before restarting — his current potassium of 5.3 mEq/L, combined with held spironolactone and acute renal impairment (reduced potassium excretion), represents a potassium-accumulating state; restarting aggressive diuresis before potassium falls below 5.0 mEq/L (ideally below 4.8 mEq/L) risks worsening potassium dynamics; (2) creatinine should be stable or trending downward, indicating that the renal ischemia phase is recovering; (3) JVP reassessment — some fluid redistribution from the interstitium to the intravascular compartment occurs after stopping diuresis, and JVP should be reassessed to guide how much diuretic intensity is now appropriate; (4) the dose should start lower than the prior 2.5× strategy — the over-diuresis episode demonstrates that this patient's hemodynamic reserve is limited and the prior dose exceeded it; a lower starting dose with careful uptitration based on urine output and hemodynamic response is the safer approach.

• Option A: Option A is incorrect: immediately restarting at 2.5× dose before potassium, creatinine, and JVP are reassessed risks reproducing the same over-diuresis scenario; the over-diuresis episode has demonstrated that this patient cannot safely tolerate aggressive high-dose diuresis without close monitoring.
• Option C: Option C is incorrect: over-diuresis does not mandate permanent restriction to oral agents; the distinction is appropriate dose and rate of diuresis, not IV versus oral administration; and transfer to a skilled nursing facility before IV diuretic use is not a standard clinical recommendation based on a single over-diuresis episode.
• Option D: Option D is incorrect: avoiding all diuretics for the remainder of the hospitalization in a patient with HFrEF and baseline fluid overload is impractical and will likely result in return of congestion before creatinine returns to baseline; the goal is careful diuretic restart at a lower dose, not permanent avoidance.
• Option E: Option E is incorrect: creatinine stability at 2.1 mg/dL does not mean the AKI has resolved (it means it has stabilized, not normalized); immediately restarting at the same aggressive dose that caused the over-diuresis — plus adding acetazolamide — is inappropriate before potassium and renal function have recovered sufficiently; acetazolamide does not prevent over-diuresis from furosemide.

ANSWER: D

Rationale:

W.J.'s discharge plan must address three domains: the diuretic agent and dose, the MRA restart, and patient education. For the diuretic: torsemide is preferred over furosemide for its consistent oral bioavailability (80–90% vs. furosemide's variable 10–100%), which reduces the day-to-day unpredictability that contributed to W.J.'s complex hospital course; the discharge dose should reflect his effective inpatient oral equivalent — not the aggressive 2.5× IV dose that produced over-diuresis in this patient with limited hemodynamic reserve. For the MRA: spironolactone should not be restarted at discharge without confirming potassium and creatinine stability, given the recent acute kidney injury (creatinine peaked at 2.1 mg/dL) and potassium instability; 5–7 day follow-up with laboratory reassessment before restarting spironolactone is appropriate, with restart criteria of potassium below 5.0 mEq/L and eGFR above 30 mL/min/1.73m². For patient education: daily weight monitoring with a specific, actionable threshold (weight gain of 2 kg over 2–3 days triggers same-day contact with the HF clinic) is the cornerstone of HF self-management and has been shown to reduce re-admissions; providing written instructions rather than verbal-only education improves adherence. Close outpatient follow-up within 1 week is mandatory after a complex hospitalization with over-diuresis and AKI. Option B is correct in most respects but uses torsemide 20 mg daily as the dose equivalent to furosemide 40 mg daily — a reasonable choice; however, Option D more fully and explicitly addresses all three discharge planning domains (diuretic choice and dose rationale, MRA restart criteria, patient education), making it the more comprehensive answer.

• Option A: Option A is incorrect: IV home furosemide infusion is not the standard AHA/ACC/HFSA recommendation after a single over-diuresis episode; it is an option for highly refractory patients without oral diuretic options; and oral bioavailability failure is not the primary etiology of W.J.'s over-diuresis.
• Option C: Option C is incorrect: discharging at the same dose that produced over-diuresis without adjusting either the diuretic or the MRA — while citing inadequate monitoring as the cause — fails to address the pharmacological dose intensity that caused the episode; the dose was genuinely excessive for this patient's hemodynamic reserve, not merely undermonitored.
• Option E: Option E is incorrect: doubling spironolactone to 50 mg at discharge in a patient with recent AKI and potassium instability is clinically dangerous — it should be held and restarted cautiously after laboratory reassessment, not increased.